Human catechol O-methyltransferase genetic variation: Gene resequencing and functional characterization of variant allozymes

Molecular Psychiatry

Volumn 9, Issue 2, 2004, Pages 151-160

  Shield, A J ^a   Thomae, B A ^a   Eckloff, B W ^b   Wieben, E D ^b   Weinshilboum, R M ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Catechol O methyltransferase; COMT; Genetic polymorphisms; Methylation; Pharmacogenetics; SNPs

Indexed keywords

ALLOENZYME; BENZOIC ACID DERIVATIVE; CATECHOL METHYLTRANSFERASE; DIHYDROBENZOIC ACID; DNA; METHIONINE; S ADENOSYLMETHIONINE; THREONINE; UNCLASSIFIED DRUG;

AFRICAN AMERICAN; ALLELE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME SUBSTRATE; EUROPEAN AMERICAN; GENE DELETION; GENE INSERTION; GENE SEQUENCE; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LIVER BIOPSY; MOLECULAR GENETICS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

ANIMALS; CATECHOL O-METHYLTRANSFERASE; COS CELLS; HAPLOTYPES; HUMANS; KIDNEY; LINKAGE (GENETICS); LIVER; METHYLATION; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); RECOMBINANT PROTEINS; SEQUENCE ANALYSIS, DNA; VARIATION (GENETICS);

EID: 1542314855     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001386     Document Type: Article

References (65)

1. Axelrod J, Tomchick R. Enzymatic O-methylation of epinephrine and other catechols. J Biol Chem 1958; 233: 702-705.
2. Guldberg HC, Marsden CA. Catechol-O-methyltransferase: pharmacological aspects and physiological role. Pharmacol Rev 1975; 27: 135-206.
3. Roth JA. Membrane-bound catechol O-methyltransferase: a reevaluation of its role in the O-methylation of the catecholamine neurotransmitter. Rev Physiol Biochem Pharmacol 1992; 120: 1-29.
4. Tenhunen J, Salminen M, Lundstrom K, Kiviluoto T, Savolainen R, Ulmanen I. Genomic organization of the human catechol-O-methyltransferase gene and its expression from two distinct promoters. Eur J Biochem 1994; 223: 1049-1059.
5. Weinshilboum RM, Raymond FA. Inheritance of low erythrocyte catechol-O-methyltransferase activity in man. Am J Hum Genet 1977; 29: 125-135.
6. Spielman RS, Weinshilboum RM, Family studies of low red cell COMT activity. Am J Hum Genet 1979; 31: 63A.
7. Floderus Y, Wetterberg L. The inheritance of human erythrocyte catechol-O-methyltransferase activity. Clin Genet 1981; 19: 392-395.
8. Siervogel RM, Weinshilboum R, Wilson AF, Elston RC. Major gene model for the inheritance of catechol-O-methyltransferase activity in five large families. Am J Med Genet 1984; 19: 315-323.
9. Weinshilboum RM, Human erythrocyte catechol-O-methyltransferase: correlation with lung and kidney activity. Life Sci 1978; 22: 625-630.
10. Boudíková B, Szumlanski C, Maidak B, Weinshilboum R. Catechol O-methyltransferase (COMT) pharmacogenetics. Clin Pharmacol Ther 1990; 48: 381-389.
11. Scanlon PD, Raymond FA, Weinshilboum RM. Catechol-O-methyltransferase: thermolabile enzyme in erythrocytes of subjects homozygous for the allele for low activity. Science 1979; 203: 63-65.
12. Spielman RS, Weinshilboum RM. Genetics of red cell COMT activity: analysis of thermal stability and family data. Am J Med Genet 1981; 10: 279-290.
13. Bertocci B, Miggiano V, Da Prada M, Dembic Z, Lahm H-W, Malherbe P. Human catechol O-methyltransferase: cloning and expression of membrane-associated form. Proc Natl Acad Sci USA 1991; 88: 1416-1420.
14. Lundström K, Salminen M, Jalanko A, Savolainen R, Ulmanen I. Cloning and characterization of human placental catechol-O-methyltransferase cDNA. DNA Cell Biol 1991; 10: 181-189.
15. Grossman MH, Emanuel BS, Budaf ML. Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1-q11.2. Genomics 1992; 12: 822-825.
16. Lachman HM, Papolos DF, Saito T, Yu Y-M, Szumlanski CL, Weinshilboum RM. Human catechol O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996; 6: 243-250.
17. Ameyaw M, Syvanen A, Ulmanen I, Ofori-Adjei D, McLeod HL. Pharmacogenetics of catechol-O-methyltransferase: frequency of low activity allele in a Ghanaian population. Hum Mutat 2000; 16: 445-446.
18. Palmatier MA, Kang AM, Kidd KK. Global variation in the frequencies of functionally different catechol O-methyltransferase alleles. Biol Psychiatry 1999; 46: 557-567.
19. Strous RD, Bark N, Parsia SS, Volavka J, Lachman HM. Analysis of a functional catechol-O-methyltransferase gene polymorphism in schizophrenia: evidence for association with aggressive and antisocial behavior. Psychiatr Res 1997; 69: 71-77.
20. Karayiorgou M, Altemus M, Galke BL, Goldman D, Murphy DL, Ott J et al. Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proc Natl Acad Sci USA 1997; 94: 4572-4575.
21. Mynett-Johnson LA, Murphy VE, Claffey E, Shields DC, McKeon P. Preliminary evidence of an association between bipolar disorder in females and the catechol-O-methyltransferase gene. Psychiatr Genet 1998; 8: 221-225.
22. Kunugi H, Nanko S, Ueki A, Otsuka E, Hattori M, Hoda F et al. High and low activity alleles of catechol O-methyltransferase gene: ethnic difference and possible association with Parkinson's disease. Neurosci Lett 1997; 221: 202-204.
23. Lavigne JA, Helzlsouer KJ, Huang H-Y, Strickland PT, Bell DA, Selmin O et al. An association between the allele coding for a low activity variant of catechol O-methyltransferase and the risk for breast cancer. Cancer Res 1997; 57: 5493-5497.
24. Craddock N, Dave S, Greening J. Association studies of bipolar disorder. Bipolar Disord 2001; 3: 284-298.
25. Schindler KM, Richter MA, Kennedy JL, Pato MT, Pato CN. Association between homozygosity at the COMT gene locus and obsessive compulsive disorder. Am J Med Genet 2000; 96: 721-724.
26. Mizuta I, Mizuta E, Yamasaki S, Kuno S, Yasuda M, Tanaka C. Meta-analysis of polymorphism of the catechol-O-methyltransferase gene in relation to the etiology of Parkinson's disease in Japan. Movement Disord 2000; 15: 1013-1014.
27. Holden C. Deconstructing schizophrenia. Science 2003; 299: 333-335.
28. Chadwick RB, Conrad MP, McGinnis MD, Johnston-Dow L, Spurgeon SL, Kronick MN. Heterozygote and mutation detection by direct automated fluorescent DNA sequencing using a mutant Taq DNA polymerase. BioTechniques 1996; 20: 676-683.
29. Nickerson DA, Tobe VO, Taylor SL. PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res 1997; 25: 2745-2751.
30. Gordon D, Abajian C, Green P. Consed: a graphical tool for sequence finishing. Genome Res 1998; 8: 195-202.
31. Devereux J, Haeberli P, Smithies O. A comprehensive set of sequence analysis programs for the VAX. Nucleic Acids Res 1984; 12: 387-395.
32. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 1989; 77: 51-59.
33. Wood TC, Aksoy IA, Aksoy S, Weinshilboum RM. Human liver thermolabile phenol sulfotransferase: cDNA cloning, expression and characterization. Biochem Biophys Res Commun 1994; 198: 1119-1127.
34. Raymond FA, Weinshilboum RM. Microassay of human erythrocyte catechol-O-methyltransferase: removal of inhibitory calcium ion with chelating resin. Clin Chim Acta 1975; 58: 185-194.
35. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
36. Wilkinson GN. Statistical estimations in enzyme kinetics. Biochem J 1961; 80: 324-332.
37. Cleland WW. Computer programmes for processing enzyme kinetic data. Nature 1963; 198: 463-465.
38. Hartl DL, Clark AG. Principles of Population Genetics, 2nd edn. Sinauer Associates, Inc.: Sunderland, MA, 1989.
39. Hendrick PW. Genetics of Populations, 2nd edn. Jones and Bartlett Publ.: Sudbury, MA, 2000, pp 396-405.
40. Long JC, Williams RC, Urbanek M. An E-M algorithm and testing strategy for multiple-locus haplotypes. Am J Hum Genet 1995; 56: 799-810.
41. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995; 12: 921-927.
42. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70: 425-434.
43. Schneider S, Roessli D, Excofier L. Arlequin: a software for population genetics data analysis, Version 2.000. Genetics and Biometry Lab, Department of Anthropology, University of Geneva, 2000.
44. McLeod HL, Fang L, Luo X, Scott EP, Evans WE. Ethnic differences in erythrocyte catechol O-methyltransferase activity in black and white Americans. J Pharmacol Exp Ther 1994; 270: 26-29.
45. Vidgren J, Svensson LA, Liljas A. Crystal structure of catechol O-methyltransferase. Nature 1994; 368: 354-358.
46. Ingrosso D, Fowler AV, Bleibaum J, Clarke S. Sequence of the D-aspartyl/L-isoaspartyl protein methyltransferase from human erythrocytes: common sequence motifs for protein, DNA, RNA and small molecule S-adenosylmethionine-dependent methyltransferases. J Biol Chem 1989; 264: 20131-20139.
47. Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Paul N et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 1999; 22: 231-238.
48. Saito S, Iida A, Sekine A, Miura Y, Sakamoto T, Ogawa C et al. Identification of 197 genetic variations in six human methyltransferase genes in the Japanese population. J Hum Genet 2001; 46: 529-537.
49. Xie T, Ho SL, Ramsden D. Characterization and implications of estrogenic down-regulation of human catechol O-methyltransferase gene transcription. Mol Pharmacol 1999; 56: 31-38.
50. Wingender E, Chen X, Hehl R, Karas H, Liebich I, Matys V et al. TRANSFAC: an integrated system for gene expression regulation. Nucleic Acids Res 2000; 28: 316-319.
51. Halushka MK, Fan J-B, Bentley K, Hsie L, Shen N, Weder A et al. Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet 1999; 22: 239-247.
52. Stephens JC, Schneider JA, Tanguay DA, Choi J, Acharya T, Stanley SE et al. Haplotype variation and linkage disquilibrium in 313 human genes. Science 2001; 293: 489-493.
53. Fullerton SM, Clark AG, Weiss KM, Nickerson DA, Taylor SL, Stengard JH et al. Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism. Am J Hum Genet 2000; 67: 881-900.
54. Freimuth RR, Eckloff B, Wieben ED, Weinshilboum RM. Human sulfotransferase SULT1C1 pharmacogenetics: gene resequencing and functional genomic studies. Pharmacogenetics 2001; 11: 747-756.
55. Thomae BA, Eckloff BW, Freimuth RR, Wieben ED, Weinshilboum RM. Human sulfotransferase SULT2A1 pharmacogenetics: genotype-to-phenotype studies. Pharmacogenomics J 2002; 2: 48-56.
56. Xu Z-H, Freimuth RR, Eckloff B, Wieben E, Weinshilboum RM. Human 3′-phosphoadenosine 5′-phosphosulfate synthetase 2 (PAPSS2) pharmacogenetics: gene resequencing, genetic polymorphisms and functional characterization of variant allozymes. Pharmacogenetics 2002; 12: 11-21.
57. Preuss CV, Wood TC, Szumlanski CL, Raftogianis RB, Otterness DM, Girard B et al. Human histamine N-methyltransferase pharmacogenetics: common genetic polymorphisms that alter activity. Mol Pharmacol 1998; 53: 708-717.
58. Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996; 15: 17-30.
59. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995; 34: 4202-4210.
60. Klemetsdal B, Staume B, Giverhaug T, Aarbakke J. Low catechol-O- methyltransferase activity in a Saami population. Eur J Clin Pharmacol 1994; 46: 231-235.
61. Goodman JE, Jensen LT, He P, Yager JD. Characterization of human soluble high and low activity catechol-O-methyltransferase catalyzed catechol estrogen methylation. Pharmacogenetics 2002; 12: 517-528.
62. Tai H-L, Fessing MY, Bonten EJ, Yanishevsky Y, d'Azzo A, Krynetski EY et al. Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C. Pharmacogenetics 1999; 9: 641-650.
63. Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, Ross D. Rapid polyubiquitination and proteosomal degradation of a mutant form of NAD(P)H:quinone oxioreductase 1. Mol Pharmacol 2001; 59: 263-268.
64. Wang L, Sullivan W, Toft D, Weinshilboum R. Thiopurine S-methyltransferase (TPMT) pharmacogenetics: role of chaperone proteins in variant allozyme degradation. Clin Pharmacol Ther 2003; 73: P29.
65. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 1998; 95: 8170-8174.